桂枝茯苓丸联合胚宝胶囊治疗慢性盆腔炎临床研究
|
摘要
目的:观察桂枝茯苓丸联合胚宝胶囊治疗慢性盆腔炎的临床治疗效果。方法:将慢性盆腔炎患者68例随机分为对照组和观察组各34例,对照组给予西医常规治疗,观察组在对照组治疗的基础上给予桂枝茯苓丸联合胚宝胶囊,2组均治疗1个月后观察2组患者临床疗效,比较2组患者腹胀、痛经、腰酸、白带异常等症状改善情况,比较2组患者炎症指标包括肿瘤坏死因子-α(TNF-α)、转化因子-β1 (TGF-β1)、C-反应蛋白(CRP)、白细胞介素-6 (IL-6)等指标的浓度变化情况。结果:治疗后,观察组总有效率88.24%,对照组总有效率73.53%,观察组治疗效果明显高于对照组(P <0.05)。治疗前,2组腹胀、痛经、腰酸、白带异常证候积分比较,差异无统计学意义(P> 0.05)。治疗后,2组腹胀、痛经、腰酸、白带异常证候积分均降低,且观察组优于对照组,差异均有统计学意义(P <0.05)。治疗前,2组炎症因子水平比较,差异无统计学意义(P> 0.05)。治疗后,2组炎症因子水平均改善,且观察组明显优于对照组,差异均有统计学意义(P <0.05)。治疗后,对照组不良反应发生率为11.76%,观察组为8.82%,2组比较,差异无统计学意义(P> 0.05)。结论:桂枝茯苓丸联合胚宝胶囊治疗慢性盆腔炎具有较好的临床疗效,可降低患者的中医证候积分和炎症反应,复发率较低,无明显不良反应。
Objective:To observe the clinical effect of Guizhi Fuling pills combined with Peibao capsules for chronic pelvic inflammation. Methods:A total of 68 cases of patients with chronic pelvic inflammation were randomly divided into the control group and the observation group, 34 cases in each group. The control group was treated with routine western medicine,and the observation group was additionally treated with Guizhi Fuling pills combined with Peibao capsules based on the treatment of the control group. After one-month treatment, the clinical effect in the two groups was observed; the improvement of symptoms such as abdominal distension,dysmenorrhea,soreness and abnormal leukorrhea in the two groups was compared;the changes of concentration of inflammatory indexes including tumor necrosis factor-α(TNF-α),transforming growth factorβ1(TGF-β1),C-reactive protein(CRP) and interleukin-6(IL-6) in the two groups were compared. Results:After treatment,the total effective rate was 88.24% in the observation group and 73.53% in the control group(P < 0.05). Before treatment,compared the syndrome scores of abdominal distension, dysmenorrhea, soreness and abnormal leukorrhea in the two groups,there was no significance in the difference(P > 0.05). After treatment,the above syndrome scores in the two groups were decreased,and the one in the observation group was better than that in the control group,differences being significant(P < 0.05). Before treatment,there was no significant difference being found in the comparison of the levels of inflammatory factors in the two groups(P > 0.05). After treatment,the levels of inflammatory factors in the two groups were improved,and the decrease in the observation group was significantly larger than that in the control group,differences being significant(P <0.05). After treatment, the incidence of adverse reactions was 11.76% in the control group and 8.82% in the observation group,there being no significance in the difference(P > 0.05). Conclusion:The therapy of Guizhi Fuling pills combined with Peibao capsules has better clinical effect in treating chronic pelvic inflammation, and can reduce the Chinese medicine syndrome scores as well as inflammatory responses with low recurrence rate and no obvious adverse reaction.
Objective:To observe the clinical effect of Guizhi Fuling pills combined with Peibao capsules for chronic pelvic inflammation. Methods:A total of 68 cases of patients with chronic pelvic inflammation were randomly divided into the control group and the observation group, 34 cases in each group. The control group was treated with routine western medicine,and the observation group was additionally treated with Guizhi Fuling pills combined with Peibao capsules based on the treatment of the control group. After one-month treatment, the clinical effect in the two groups was observed; the improvement of symptoms such as abdominal distension,dysmenorrhea,soreness and abnormal leukorrhea in the two groups was compared;the changes of concentration of inflammatory indexes including tumor necrosis factor-α(TNF-α),transforming growth factorβ1(TGF-β1),C-reactive protein(CRP) and interleukin-6(IL-6) in the two groups were compared. Results:After treatment,the total effective rate was 88.24% in the observation group and 73.53% in the control group(P < 0.05). Before treatment,compared the syndrome scores of abdominal distension, dysmenorrhea, soreness and abnormal leukorrhea in the two groups,there was no significance in the difference(P > 0.05). After treatment,the above syndrome scores in the two groups were decreased,and the one in the observation group was better than that in the control group,differences being significant(P < 0.05). Before treatment,there was no significant difference being found in the comparison of the levels of inflammatory factors in the two groups(P > 0.05). After treatment,the levels of inflammatory factors in the two groups were improved,and the decrease in the observation group was significantly larger than that in the control group,differences being significant(P <0.05). After treatment, the incidence of adverse reactions was 11.76% in the control group and 8.82% in the observation group,there being no significance in the difference(P > 0.05). Conclusion:The therapy of Guizhi Fuling pills combined with Peibao capsules has better clinical effect in treating chronic pelvic inflammation, and can reduce the Chinese medicine syndrome scores as well as inflammatory responses with low recurrence rate and no obvious adverse reaction.
引文
[1]黄蒙宇,李双,叶品丽.下瘀血汤合桂枝茯苓丸加味治疗盆腔瘀血综合征疗效观察[J].新中医,2015,47(6):172-173.
[2]樊尚荣,张慧萍.2010年美国疾病控制中心盆腔炎治疗指南[J].中国全科医学,2011,14(11):1165-1166.
[3]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:68-73.
[4]王大为,公真,张蕾,等.桂枝茯苓胶囊对原发性痛经患者炎症因子的影响[J].中国临床药理学与治疗学,2016,21(4):441-444.
[5]崔玉丹,蔡英姬,金河奎,等.胚宝胶囊免疫作用的实验研究[J].中国中医药科技,2000,7(3):149-150.
[2]樊尚荣,张慧萍.2010年美国疾病控制中心盆腔炎治疗指南[J].中国全科医学,2011,14(11):1165-1166.
[3]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:68-73.
[4]王大为,公真,张蕾,等.桂枝茯苓胶囊对原发性痛经患者炎症因子的影响[J].中国临床药理学与治疗学,2016,21(4):441-444.
[5]崔玉丹,蔡英姬,金河奎,等.胚宝胶囊免疫作用的实验研究[J].中国中医药科技,2000,7(3):149-150.